Business Context and Reporting Period
Company: RELMADA THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: September 28, 2017 (Event dates: September 28, 2017 and October 4, 2017)
Context: The Company entered into a Material Definitive Agreement to raise capital through the issuance of convertible notes and warrants to accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds Received: $6,840,000
- Debt Instrument: 7% Convertible Promissory Notes totaling $6,890,000 principal.
- Warrants Issued: 4,593,333 warrants to purchase common stock at an exercise price of $1.50 per share.
- Note Maturity: Two years from issuance.
- Placement Agent Fees: $584,500 cash fee plus warrants for 779,333 shares; $58,450 expense allowance.
- Liquidity Impact: Immediate cash inflow of $6.84 million.
Material Changes and Terms
The filing details a significant change in the Company's capital structure through unregistered sales of equity securities (Rule 506 of Regulation D). Key terms include:
- Automatic Conversion Trigger: Notes automatically convert if the Company raises $10,000,000 or more in gross proceeds in an equity financing prior to maturity.
- Conversion Price: Upon automatic conversion, the price is the lower of $0.75 or 80% of the price per share paid in the triggering equity financing.
- Investor Option: Investors may elect to convert notes into common stock at $0.75 per share anytime on or before the Maturity Date.
- Subordination: Notes are subordinated to all senior debt obligations.
Outlook, Risks, and Contingencies
- Future Financing Contingency: The debt structure is contingent on a future "Equity Financing" of at least $10 million to trigger automatic conversion.
- Regulatory Status: Securities were not registered under the Securities Act of 1933 and were sold solely to accredited investors without general solicitation.
- Dilution Risk: The issuance of warrants and the potential conversion of notes at a discount ($0.75) to the warrant exercise price ($1.50) presents potential dilution to existing shareholders.
- Management Commentary: The filing does not provide specific management commentary on operational outlook, focusing strictly on the transaction mechanics.
Investor Verification Checklist
- Verify the exact closing date and final principal amount of the $6.89 million note issuance.
- Confirm the status of any subsequent equity financing to determine if the $10 million automatic conversion trigger has been met.
- Review the full Note and Warrant Purchase Agreement (exhibits to the Form 10-Q for the quarter ended September 30, 2017) for detailed covenants.
- Assess the Company's current cash burn rate relative to the $6.84 million proceeds to evaluate runway.
- Monitor for any senior debt obligations that would take precedence over these convertible notes.